Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.

Bénédicte GaboritP AncelA E AbdullahF MauriceI AbdesselamA CalenA SoghomonianM HoussaysI VarletM EisingerA LasbleizF PeirettiC E BornetY LefurL PiniS RapacchiM BernardN ResseguierP DarmonF KoberA Dutour

Published in: Cardiovascular diabetology (2021)

EMPA effectively reduced liver fat in mice and humans without changing epicardial, myocardial fat or myocardial energetics, rebutting the thrifty substrate hypothesis for cardiovascular protection of SGLT2 inhibitors. Trial registration NCT, NCT03118336. Registered 18 April 2017, https://clinicaltrials.gov/ct2/show/NCT03118336.

Keyphrases

adipose tissue
type diabetes
left ventricular
fatty acid
clinical trial
computed tomography
study protocol
heart failure
insulin resistance
magnetic resonance imaging
phase iii
randomized controlled trial
glycemic control
phase ii
metabolic syndrome
contrast enhanced
open label